The Management of Atopic Dermatitis in Primary Care Paediatrics

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition affecting up to 20% of children in the United Kingdom and represents a substantial burden in paediatric primary care. Beyond cutaneous manifestations, AD significantly impacts sleep, behaviour, and quality of life in affected children and their families. Despite its high prevalence, variability in presentation and concerns surrounding treatment safety contribute to inconsistent management and therapeutic hesitancy. This review aims to evaluate the diagnosis and management of paediatric AD, with a focus on evidence-based treatment strategies and their role in improving clinical and patient-centred outcomes.

Methods: A narrative literature review was conducted using PubMed, including clinical guidelines, randomised controlled trials, and systematic reviews published since 2000. Selected landmark studies and authoritative resources were also included to reflect current paediatric practice.

Learning Points: Management of paediatric AD requires a stepwise, severity-based approach tailored to the individual child. Regular use of emollients remains the cornerstone of therapy, supporting skin barrier function and reducing flare frequency. Topical corticosteroids are first-line for acute flares and demonstrate strong efficacy and safety in children when used appropriately; however, “steroid phobia” among caregivers and clinicians continues to limit optimal use. Topical calcineurin inhibitors, including tacrolimus and pimecrolimus, provide effective steroid-sparing alternatives, particularly for sensitive areas such as the face and flexures. In moderate-to-severe disease, escalation to secondary care may be required, with phototherapy and systemic immunosuppressants such as methotrexate, ciclosporin, and azathioprine demonstrating clinical benefit. Biologic therapy with dupilumab has shown significant improvements in disease severity, pruritus, and quality of life in paediatric populations, representing a major advancement in treatment. However, current evidence is limited by moderate sample sizes and underrepresentation of diverse populations, which may affect generalisability.

Conclusion: Effective management requires early diagnosis, appropriate treatment selection, timely escalation, and a holistic approach addressing comorbid atopic disease and psychosocial impact. Improving clinician confidence and caregiver education is essential to optimise adherence and long-term outcomes. Further research is needed to support personalised and equitable management strategies in children.